Lupin is a USD 2.06 billion innovation led transnational pharmaceutical major producing and developing a wide range of branded and generic formulations as well as biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment. Lupin is the 6th largest and fastest growing top 5 generics player in the US (5.3% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The Company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS). For the financial year ended March 2014, Lupin's Consolidated turnover and Profit after Tax were Rs. 120,600 million (USD 2.06 billion) and Rs. 18,364 million (USD 393 million) respectively.

Show more
Type
Public
HQ
Mumbai, IN
Founded
1968
Size (employees)
16,792 (est)
Website
lupin.com
Lupin was founded in 1968 and is headquartered in Mumbai, IN
Report incorrect company information

Lupin Office Locations

Lupin has offices in Mumbai, Baltimore and Zug
Mumbai, IN (HQ)
Laxmi Towers BKC Road
Mumbai, IN
Highway House Jawaharlal Nehru Rd
Zug, CH
1 Landis + Gyr-Strasse
Show all (4)
Report incorrect company information

Lupin Online and Social Media Presence

Embed Graph
Report incorrect company information

Lupin News and Updates

Lupin Ltd spurts 4.77%, up for third straight session

The stock is quoting at Rs 876.7, up 4.77% on the day as on 12:49 IST on the NSE. Lupin Ltd is down 6.57% in last one year as compared to a 16.52% gain in NIFTY and a 12.5% gain in the Nifty Pharma index.

Lupin Ltd drops for fifth straight session

The stock is quoting at Rs 811.15, down 1.42% on the day as on 13:19 IST on the NSE. Lupin Ltd tumbled 13.79% in last one year as compared to a 17.88% rally in NIFTY and a 7.37% spurt in the Nifty Pharma index.

Lupin Q1 result points to a tough year ahead

The decline in Lupin’s Q1 result can be attributed to lower share of sales of some of its key generic products, including TamiFlu as the flu season is now over

Lupin consolidated net profit declines 43.11% in the June 2018 quarter

Sales decline 0.85% to Rs 3774.57 crore

Lupin standalone net profit rises 21.28% in the June 2018 quarter

Sales rise 3.05% to Rs 2512.00 crore

Credit Suisse Downgrades Lupin After Weak Earnings

Credit Suisse has downgraded the stock to ‘Underperform’ from ‘Neutral’ and revised the target price to Rs 715 from Rs 770.
Show more
Report incorrect company information

Lupin Company Life and Culture

Report incorrect company information